SparingVision logo avec baseline HD.jpg
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
20. April 2021 07:00 ET | SparingVision
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
SparingVision logo avec baseline HD.jpg
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
20. April 2021 01:00 ET | SparingVision
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis...
SparingVision logo avec baseline HD.jpg
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19. März 2021 08:00 ET | SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision logo avec baseline HD.jpg
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
19. März 2021 02:00 ET | SparingVision
SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting Paris, March 19, 2021 – SparingVision (“the Company”), a genomic...
SparingVision logo avec baseline HD.jpg
SparingVision Conference Participation in H1 2021
16. Februar 2021 07:00 ET | SparingVision
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
SparingVision logo avec baseline HD.jpg
SparingVision Conference Participation in H1 2021
16. Februar 2021 01:00 ET | SparingVision
SparingVision Conference Participation in H1 2021 Paris, February 16, 2021 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases,...
SparingVision logo avec baseline HD.jpg
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
04. Februar 2021 01:00 ET | SparingVision
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision             Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...
SparingVision logo avec baseline HD.jpg
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
04. Februar 2021 01:00 ET | SparingVision
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision             Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of...
SparingVision logo avec baseline HD.jpg
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29. Januar 2021 07:00 ET | SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board                   Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...
SparingVision logo avec baseline HD.jpg
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
29. Januar 2021 01:00 ET | SparingVision
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board                   Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board ...